Improving Ventricular Tachycardia Ablation with Optimised Decrement Evoked Potential DeEP Mapping for Patients with Structural Heart Disease and Implantable Cardiac Devices

What this Trial Is About

Ventricular tachycardia VT is a dangerous heart rhythm disorder that can be life-threatening. This research aims to improve how doctors find the damaged heart areas causing VT episodes in patients with structural heart disease. The study focuses on a new method that detects special heart signals called decrementing evoked potentials DeEPs to better guide VT ablation procedures. The goal is to reduce VT episodes in patients who have implantable cardiac defibrillators ICDs. The treatment being studied is called Optimised DeEP-guided ablation, which uses detailed computer-generated maps to locate and remove diseased heart tissue through controlled heating. This procedure is performed in specialized cardiac catheter laboratories using Abbott intracardiac mapping catheters and Ensite mapping systems. The ablation targets areas identified by DeEP signals. The procedure is part of the patients standard care, performed either urgently or electively. Participants will be monitored for 12 months after the ablation to assess the procedures success in preventing VT episodes. Quality of life will be measured before and after treatment using questionnaires. The main outcome measured is the acute success rate from the start to the end of the VT ablation procedure. Patients will receive routine follow-up as part of their care, with the study conducted by multiple cardiac centers in the UK to gather comprehensive data on this new mapping approach.

Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Structural Heart Disease VT